Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial

Alzheimer Disease and Associated Disorders
Sandi CuloB G Pollock

Abstract

Sensitivity to psychotropic medications presents a therapeutic challenge when treating neuropsychiatric symptoms in patients with dementia with Lewy bodies (DLB). We compared under randomized, double-blinded conditions the tolerability and efficacy of citalopram and risperidone in the treatment of behavioral and psychotic symptoms in patients with DLB and Alzheimer disease (AD). Thirty-one participants with DLB and 66 with AD hospitalized for behavioral disturbance were treated under randomized, double-blind conditions with citalopram or risperidone for up to 12 weeks. Neuropsychiatric symptoms were assessed with the nursing home version of the Neuropsychiatric Inventory (NPI) and the Clinical Global Impression of Change (CGIC). Side effects were measured using the UKU Side Effect Rating Scale. A significantly higher proportion of participants with DLB (68%) than with AD (50%) discontinued the study prematurely. Discontinuation rates were comparable in DLB participants treated with citalopram (71%) or risperidone (65%). However, participants with DLB randomized to risperidone experienced a higher overall burden of side effects. Scores on the NPI and the CGIC worsened in DLB participants and improved in those with AD. Most patie...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Dec 1, 1990·The British Journal of Psychiatry : the Journal of Mental Science·A L Nyth, C G Gottfries
Jan 1, 1991·Annals of the New York Academy of Sciences·C G Gottfries, A L Nyth
Sep 9, 1995·Lancet·I G McKeithR W Harrison
Jan 1, 1996·International Psychogeriatrics·S R AuerB Reisberg
Jan 29, 2000·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·S WoodJ F Schnelle
Oct 21, 2000·Progress in Neuro-psychopharmacology & Biological Psychiatry·G SechiG Rosati
Feb 15, 2002·Dementia and Geriatric Cognitive Disorders·Jeffrey L CummingsW Scott Clark
Jan 30, 2003·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Masayuki Morikawa, Toshifumi Kishimoto
Dec 23, 2004·Clinical Neuropharmacology·Barbara CollinsErich Mohr
Apr 9, 2005·Journal of the American Geriatrics Society·Makoto Tanaka, Toru Kita
Oct 21, 2005·Neurology·I G McKeithUNKNOWN Consortium on DLB
Nov 10, 2006·Journal of Psychiatric Research·Sati MazumdarCharles F Reynolds
Feb 1, 2007·International Journal of Geriatric Psychiatry·Mani BhasinIan McKeith
Mar 16, 2007·Dementia and Geriatric Cognitive Disorders·Corinne FischerSean B Rourke
Apr 25, 2007·Neurology·Roger KurlanUNKNOWN Alzheimer's Disease Cooperative Study Group
Sep 12, 2007·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Bruce G PollockKimberly A Huber
Nov 14, 2007·Expert Review of Neurotherapeutics·Rawan Tarawneh, James E Galvin

❮ Previous
Next ❯

Citations

Jul 19, 2012·Current Neurology and Neuroscience Reports·D AarslandP Svenningsson
May 31, 2012·Current Psychiatry Reports·Abhilash K DesaiGeorge T Grossberg
Oct 5, 2011·The Journal of Nutrition, Health & Aging·C ArbusUNKNOWN REAL.FR Group
Jan 8, 2013·The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry·Zahinoor IsmailBenoit H Mulsant
May 4, 2011·The Psychiatric Clinics of North America·Alana IglewiczDilip V Jeste
Sep 4, 2015·Harvard Review of Psychiatry·Mark A ColijnGeorge T Grossberg
Feb 18, 2016·Expert Review of Neurotherapeutics·Radoslaw Magierski, Tomasz Sobow
May 23, 2014·Expert Opinion on Pharmacotherapy·Leora L Borek, Joseph H Friedman
Jun 2, 2015·Alzheimer's Research & Therapy·Brendon P Boot
Jan 24, 2017·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Martin R Farlow, Tatyana A Shamliyan
Mar 25, 2011·American Journal of Alzheimer's Disease and Other Dementias·Genevieve HenryRajesh R Tampi
Nov 17, 2017·Psychological Medicine·Michael H ConnorsJohn T O'Brien
Sep 14, 2018·Expert Opinion on Pharmacotherapy·Giovanni PalermoUbaldo Bonuccelli
Mar 9, 2019·The Australian and New Zealand Journal of Psychiatry·Kai Sin ChinRosie Watson
Oct 15, 2014·International Psychogeriatrics·Jeffrey CummingsUNKNOWN International Psychogeriatric Association
Sep 27, 2018·Journal of Clinical Nursing·Leonhard H SchützNils Lahmann
Apr 2, 2015·Health & Social Care in the Community·Claudia DinandMargareta Halek
Sep 13, 2019·Neurology and Therapy·Amir Abbas Tahami MonfaredDarren Joe
Dec 18, 2019·Psychiatry and Clinical Neurosciences·Natalie SeilerBrian O'Donoghue
Apr 19, 2011·Aging & Mental Health·Ramona Lucas-CarrascoMeryl Brod
Jun 27, 2019·Expert Review of Neurotherapeutics·Isabella BerardelliGiovanni Fabbrini
Oct 16, 2019·Expert Opinion on Investigational Drugs·Garam LeeMarwan N Sabbagh
Jun 5, 2020·Neurology and Therapy·Amir A Tahami MonfaredRichard Perry
May 18, 2019·Drugs in R&D·Stephanie V PhanSusan C Fagan
Jun 2, 2020·Parkinsonism & Related Disorders·Kevin Kyle, Jeff M Bronstein

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved